UC12-0033: A genotype-guided dosing study of mFOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Aims: This study is being done to determine whether a certain dose of a chemotherapy drug (irinotecan) can be tolerated as part of a combination of drugs. There is a combination of chemotherapy drugs often used to treat your type of cancer. 5-FU, leucovorin, irinotecan and oxaliplatin; the combination is known as "FOLFIRINOX." FOLFIRINOX is a current regimen used for patients with advanced pancreatic cancer. It was recently shown in a separate clinical trial to increase survival compared to another commonly used drug in pancreatic cancer, gemcitabine. FOLFIRINOX is also a reasonable regimen for patients with other advanced cancers of the gastrointestinal tract, including colon cancer, rectal cancer, esophagus cancer, stomach cancer, gall bladder cancer, bile duct cancer, ampullary cancer, and cancers with an unknown primary location.
Diagnosis: Esophageal Cancer 
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH12-266
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

N1048: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality
Aims: The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLOX (the drugs 5-fluorouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely since 2002 to treat patients with advanced colorectal cancer.
Diagnosis: Advanced Colorectal Cancer
Principal Investigator:
 Joseph Muldoon, MD
IRB Approval Number: EH12-468
Sponsor: Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

UC14-0594: PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma
Aims: The purpose of this study is investigate the combination of chemotherapy drugs known as FOLFIRINOX as a treatment for gastric/esophagogastric junction or esophageal cancer.
Diagnosis: Gastric/esophagogastric junction or esophageal cancer.
Principal Investigator: Robert Marsh, MD 
IRB Approval Number: EH15-389
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

UC14-0595: A Genotype-Guided Dosing Study of FOLFIRABRAX In Previously Untreated Patients with Advanced Gastrointestinal Malignancies
Aims: The purpose of this study is investigate the combination of chemotherapy drugs known as FOLFIRABRAX as a treatment for advanced gastrointestinal malignancies and see if genotypes can guide physicians to the best doses for the patient.
Diagnosis: Gastronintestinal cancers that have not been treated
Principal Investigator: Robert Marsh, MD 
IRB Approval Number: EH16-317
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

A021501: Preoperative Extended Chemotherapy Versus Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Aims: The purpose of this  study is to compare any good and bad effects of using chemotherapy alone compared to chemotherapy and radiation prior to surgery.
Diagnosis: Pancreas
Principal Investigator:
 Robert Marsh, MD
IRB Approval Number: EH17-183
Sponsor: Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

S1513: Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Aims: The purpose is to compare the good and bad effects of using the investigational drug, ABT-888(Veliparib) with modified FOLFIRI compared to using FOLFIRI alone (standard chemotherapy)
Diagnosis: Metastatic Pancreatic Cancer
Principal Investigator:
 Marisa Hill, MD
IRB Approval Number: EH17-215
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

The Pancreatic Sample Repository
Aims: Collect blood, pancreatic secretions and pancreatic tissue from patients undergoing surgery for pancreatic diseases, including cancer and store these samples in a repository for future studies done at NorthShore or at collaborating institutions
 Diagnosis: Any pancreatic disease
Principal Investigator: Karen Kaul, MD 
IRB Approval Number: EH02-186
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Susan Jane Stocker, LPN, BLS,CCRP at 847.570.1322, sstocker@northshore.org or Gnathan Carpenter, RN at 847.570.2949, gcarpenter@northshore.org
Open to Enrollment: Yes

Clinical Pancreatic Cancer Database
Aims: Capture, review, and compare medical information, including symptoms, treatments and complications that people with pancreatic diseases have and store this information for future research studies done at NorthShore or iwth collaborating institutions.
Diagnosis: Any pancreatic disease
Principal Investigator: Mark S. Talamonti, MD
IRB Approval Number: EH08-197T
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact Susan Jane Stocker, LPN, BLS,CCRP at 847.570.1322, sstocker@northshore.org or Gnathan Carpenter, RN at 847.570.2949, gcarpenter@northshore.org
Open to Enrollment: Yes

A Phase III Clinical Trial of Intr-arterial TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC)
Aims: The purpose of this study is to evaluate TheraSphere® in the treatment of patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib therapy is planned. Patients will be randomized to receive either TheraSphere and sorafenib or sorafenib alone. TheraSphere is a medical device that delivers radiation directly to the liver tumor to slow or stop the growth of the tumor.
Diagnosis: Hepatocelluar Carcinoma (HCC)
Principal Investigator: Claus Fimmel, MD
IRB Approval Number: EH14-254
Sponsor: BTG International Inc./ Biocompatibles UK Ltd
Contact: Interested patients should contact Colleen Leonard at 847.570.3558, cleonard@northshore.org 
Open to Enrollment: Yes